D. E. Shaw & Co., Inc. Myriad Genetics Inc Transaction History
D. E. Shaw & Co., Inc.
- $156 Billion
- Q3 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Myriad Genetics Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 4,559,136 shares of MYGN stock, worth $30.6 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
4,559,136
Previous 4,511,497
1.06%
Holding current value
$30.6 Million
Previous $24 Million
37.59%
% of portfolio
0.02%
Previous 0.02%
Shares
33 transactions
Others Institutions Holding MYGN
# of Institutions
237Shares Held
92.1MCall Options Held
86.1KPut Options Held
18.9K-
Black Rock Inc. New York, NY15.2MShares$102 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.88MShares$52.9 Million0.0% of portfolio
-
State Street Corp Boston, MA4.98MShares$33.4 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.75MShares$31.9 Million0.02% of portfolio
-
Glenview Capital Management, LLC New York, NY4.59MShares$30.8 Million0.75% of portfolio
About MYRIAD GENETICS INC
- Ticker MYGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 80,634,800
- Market Cap $541M
- Description
- Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...